Hengrui Pharma Raises $1.3 Billion in Hong Kong IPO, Over-subscribed by 455 Times

Jiangsu Hengrui Pharmaceuticals, a leading pharmaceutical company in China, successfully completed its Initial Public Offering (IPO) in Hong Kong on May 23, 2025. The company raised a substantial $1.3 billion at the upper price range of the offering. This success was driven by significant market interest and investor confidence in the healthcare sector’s potential for future growth.